XOTC:CYOE CytoCore Inc Quarterly Report 10-Q/A Filing - 6/30/2012

Effective Date 6/30/2012

XOTC:CYOE (CytoCore Inc): Fair Value Estimate
Premium
XOTC:CYOE (CytoCore Inc): Consider Buying
Premium
XOTC:CYOE (CytoCore Inc): Consider Selling
Premium
XOTC:CYOE (CytoCore Inc): Fair Value Uncertainty
Premium
XOTC:CYOE (CytoCore Inc): Economic Moat
Premium
XOTC:CYOE (CytoCore Inc): Stewardship
Premium
 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-Q/A

(Amendment No. 1)

(Mark One)

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2012

 

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to ____________.

 

Commission File number 0-935


 

CYTOCORE, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware     36-4296006
(State or Other Jurisdiction of   (I.R.S. Employer
Incorporation or Organization)    Identification No.)

 

414 North Orleans Street, Suite 510

Chicago, IL 60654

(Address of Principal Executive Offices)

 

(312) 222-9550

(Registrant’s Telephone Number, Including Area Code)

 

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x No ¨ (not required)

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rue 12b-2 of the Exchange Act. (Check one):

 

Large Accelerated Filer ¨ Accelerated Filer  ¨ 
   
Non-Accelerated Filer ¨ Smaller Reporting Company x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

 

The number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date:

common STOCK, $0.001 par value, AT SEPTEMBER 5, 2012: 72,397,957

 
 

Explanatory Note

 

This Amendment No. 1 on Form 10-Q/A amends the Quarterly Report on Form 10-Q of Cytocore, Inc. for the quarter ended June 30, 2012, filed with the Securities and Exchange Commission on August 20, 2012 (the "Form 10-Q") for the sole purpose of furnishing the interactive data files as Exhibit 101 in accordance with Rule 405 of Regulation S-T. Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

 

No other changes have been made to the Form 10-Q. This Form 10-Q/A speaks as of the original filing date of the Form 10-Q, does not reflect events which may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the Form 10-Q.

 

PART II. OTHER INFORMATION

 

Item 6. Exhibits

   
Exhibit  
Number Description
   
31.1 Section 302 certification by principal executive and chief financial officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002 (incorporated by reference to Exhibit 31.1 to the Annual Report on Form 10-Q for the quarter ended June 30, 2012, as filed with the Commission on August 20, 2012).
   
32.1 Section 906 certification by principal executive and chief financial officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002 (incorporated by reference to Exhibit 32.1 to the Annual Report on Form 10-Q for the quarter ended June 30, 2012, as filed with the Commission on August 20, 2012).
   
101.INS* XBRL Instance Document
   
101.SCH* XBRL Taxonomy Extension Schema Document
   
101.CAL* XBRL Taxonomy Extension Calculation Linkbase Document
   
101.DEF* XBRL Taxonomy Extension Definition Linkbase Document
   
101.LAB* XBRL Taxonomy Extension Label Linkbase Document
   
101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document

 

*Filed herewith

 

Pursuant to Rule 406T of Regulation S-T, the foregoing interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

 

 
 

 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

   
  CytoCore, Inc.
   
   
  /s/ Robert F. McCullough, Jr.
       Robert F. McCullough, Jr.
       Chief Executive Officer and
       Chief Financial Officer
         

 

Date: September 5, 2012

 

 
 

EXHIBIT INDEX

 

 

   
Exhibit  
Number Description
   
31.1 Section 302 certification by principal executive and chief financial officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002 (incorporated by reference to Exhibit 31.1 to the Annual Report on Form 10-Q for the quarter ended June 30, 2012, as filed with the Commission on August 20, 2012).
   
32.1 Section 906 certification by principal executive and chief financial officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002 (incorporated by reference to Exhibit 32.1 to the Annual Report on Form 10-Q for the quarter ended June 30, 2012, as filed with the Commission on August 20, 2012).
   
101.INS* XBRL Instance Document
   
101.SCH* XBRL Taxonomy Extension Schema Document
   
101.CAL* XBRL Taxonomy Extension Calculation Linkbase Document
   
101.DEF* XBRL Taxonomy Extension Definition Linkbase Document
   
101.LAB* XBRL Taxonomy Extension Label Linkbase Document
   
101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document

 

 

 

 

XOTC:CYOE CytoCore Inc Quarterly Report 10-Q/A Filling

CytoCore Inc XOTC:CYOE Stock - Get Quarterly Report SEC Filing of CytoCore Inc XOTC:CYOE stocks, including company profile, shares outstanding, strategy, business segments, operations, officers, consolidated financial statements, financial notes and ownership information.

XOTC:CYOE CytoCore Inc Quarterly Report 10-Q/A Filing - 6/30/2012
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Title |  Date |  Company |  Symbol |  Interest |  Popularity

Previous: XOTC:CYOE CytoCore Inc Quarterly Report 10-Q Filing - 6/30/2012  |  Next: XOTC:CYRP Quarterly Report 10-Q Filing - 3/31/2012